New therapeutic perspectives in HBV: when to stop NAs
The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first‐line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virolog...
Gespeichert in:
| Veröffentlicht in: | Liver international 2014-02, Vol.34 (s1), p.146-153 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 153 |
|---|---|
| container_issue | s1 |
| container_start_page | 146 |
| container_title | Liver international |
| container_volume | 34 |
| creator | Pérez-Cameo, Cristina Pons, Mònica Esteban, Rafael |
| description | The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first‐line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virological relapse after discontinuation. Because of these reasons, long‐term treatment is needed. They are well‐tolerated oral drugs, and it seems they do not produce important side‐effects in long‐term administration. The duration of NA treatment remains unclear, nevertheless, in some patients NAs can be stopped with a low rate of relapse. HBeAg‐positive patients could discontinue NA therapy if they achieved HBeAg seroclearance and maintain undetectable HBV DNA. For HBeAg‐negative patients, to stop NA treatment is not recommended. In addition to other factors, serum HBsAg titres during treatment have recently been proposed to guide NA‐based therapy duration in selected patients. All patients could be stopped from taking treatment if they achieve HBsAg loss. |
| doi_str_mv | 10.1111/liv.12398 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1496886134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490753105</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3578-b0bd3746cf3fb0f9a2492a9dd83e711a666b7983751b222ad4b70d3ba91c6c013</originalsourceid><addsrcrecordid>eNqNkEFPwkAQhTdGI4ge_AOmRy-F3Z222_WGqEDS1JggJl42u-02rBZauy3Iv7cCcnYu85L53kzmIXRNcJ-0NcjNuk8o8PAEdYnHQhcokNOjptBBF9Z-YEw498k56lAPGGBOu8iP9capF7qSpW5qkzilrmypk9qstXXMypncz--czUKvnLpwbF2UTjy0l-gsk7nVV4feQ69Pj7PRxI2ex9PRMHIN-O1phVUKzAuSDDKFMy6px6nkaRqCZoTIIAgU4yEwnyhKqUw9xXAKSnKSBAkm0EO3-71lVXw12tZiaWyi81yudNFYQTwehGFAwPsPipkPBPstenNAG7XUqSgrs5TVVvyl0gKDPbAxud4e5wSL37hFG7fYxS2i6XwnWoe7dxhb6--jQ1afImDtf-ItHouHCczeWRSLF_gB4ap-Zg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490753105</pqid></control><display><type>article</type><title>New therapeutic perspectives in HBV: when to stop NAs</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Pérez-Cameo, Cristina ; Pons, Mònica ; Esteban, Rafael</creator><creatorcontrib>Pérez-Cameo, Cristina ; Pons, Mònica ; Esteban, Rafael</creatorcontrib><description>The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first‐line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virological relapse after discontinuation. Because of these reasons, long‐term treatment is needed. They are well‐tolerated oral drugs, and it seems they do not produce important side‐effects in long‐term administration. The duration of NA treatment remains unclear, nevertheless, in some patients NAs can be stopped with a low rate of relapse. HBeAg‐positive patients could discontinue NA therapy if they achieved HBeAg seroclearance and maintain undetectable HBV DNA. For HBeAg‐negative patients, to stop NA treatment is not recommended. In addition to other factors, serum HBsAg titres during treatment have recently been proposed to guide NA‐based therapy duration in selected patients. All patients could be stopped from taking treatment if they achieve HBsAg loss.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12398</identifier><identifier>PMID: 24373092</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adenine - analogs & derivatives ; Algorithms ; Antiviral Agents - therapeutic use ; Biomarkers - blood ; chronic hepatitis B ; DNA ; DNA, Viral - blood ; Drug Therapy, Combination - methods ; Drug Therapy, Combination - trends ; Guanine - analogs & derivatives ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - drug therapy ; Humans ; Interferon-alpha - therapeutic use ; Lamivudine ; nucleos(t)ide analogues ; Nucleosides - therapeutic use ; Organophosphonates ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins - therapeutic use ; Tenofovir ; Thymidine - analogs & derivatives ; treatment</subject><ispartof>Liver international, 2014-02, Vol.34 (s1), p.146-153</ispartof><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12398$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12398$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24373092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez-Cameo, Cristina</creatorcontrib><creatorcontrib>Pons, Mònica</creatorcontrib><creatorcontrib>Esteban, Rafael</creatorcontrib><title>New therapeutic perspectives in HBV: when to stop NAs</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first‐line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virological relapse after discontinuation. Because of these reasons, long‐term treatment is needed. They are well‐tolerated oral drugs, and it seems they do not produce important side‐effects in long‐term administration. The duration of NA treatment remains unclear, nevertheless, in some patients NAs can be stopped with a low rate of relapse. HBeAg‐positive patients could discontinue NA therapy if they achieved HBeAg seroclearance and maintain undetectable HBV DNA. For HBeAg‐negative patients, to stop NA treatment is not recommended. In addition to other factors, serum HBsAg titres during treatment have recently been proposed to guide NA‐based therapy duration in selected patients. All patients could be stopped from taking treatment if they achieve HBsAg loss.</description><subject>Adenine - analogs & derivatives</subject><subject>Algorithms</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>chronic hepatitis B</subject><subject>DNA</subject><subject>DNA, Viral - blood</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug Therapy, Combination - trends</subject><subject>Guanine - analogs & derivatives</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lamivudine</subject><subject>nucleos(t)ide analogues</subject><subject>Nucleosides - therapeutic use</subject><subject>Organophosphonates</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Tenofovir</subject><subject>Thymidine - analogs & derivatives</subject><subject>treatment</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEFPwkAQhTdGI4ge_AOmRy-F3Z222_WGqEDS1JggJl42u-02rBZauy3Iv7cCcnYu85L53kzmIXRNcJ-0NcjNuk8o8PAEdYnHQhcokNOjptBBF9Z-YEw498k56lAPGGBOu8iP9capF7qSpW5qkzilrmypk9qstXXMypncz--czUKvnLpwbF2UTjy0l-gsk7nVV4feQ69Pj7PRxI2ex9PRMHIN-O1phVUKzAuSDDKFMy6px6nkaRqCZoTIIAgU4yEwnyhKqUw9xXAKSnKSBAkm0EO3-71lVXw12tZiaWyi81yudNFYQTwehGFAwPsPipkPBPstenNAG7XUqSgrs5TVVvyl0gKDPbAxud4e5wSL37hFG7fYxS2i6XwnWoe7dxhb6--jQ1afImDtf-ItHouHCczeWRSLF_gB4ap-Zg</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Pérez-Cameo, Cristina</creator><creator>Pons, Mònica</creator><creator>Esteban, Rafael</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201402</creationdate><title>New therapeutic perspectives in HBV: when to stop NAs</title><author>Pérez-Cameo, Cristina ; Pons, Mònica ; Esteban, Rafael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3578-b0bd3746cf3fb0f9a2492a9dd83e711a666b7983751b222ad4b70d3ba91c6c013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Algorithms</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>chronic hepatitis B</topic><topic>DNA</topic><topic>DNA, Viral - blood</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug Therapy, Combination - trends</topic><topic>Guanine - analogs & derivatives</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lamivudine</topic><topic>nucleos(t)ide analogues</topic><topic>Nucleosides - therapeutic use</topic><topic>Organophosphonates</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Tenofovir</topic><topic>Thymidine - analogs & derivatives</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez-Cameo, Cristina</creatorcontrib><creatorcontrib>Pons, Mònica</creatorcontrib><creatorcontrib>Esteban, Rafael</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez-Cameo, Cristina</au><au>Pons, Mònica</au><au>Esteban, Rafael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New therapeutic perspectives in HBV: when to stop NAs</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2014-02</date><risdate>2014</risdate><volume>34</volume><issue>s1</issue><spage>146</spage><epage>153</epage><pages>146-153</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first‐line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virological relapse after discontinuation. Because of these reasons, long‐term treatment is needed. They are well‐tolerated oral drugs, and it seems they do not produce important side‐effects in long‐term administration. The duration of NA treatment remains unclear, nevertheless, in some patients NAs can be stopped with a low rate of relapse. HBeAg‐positive patients could discontinue NA therapy if they achieved HBeAg seroclearance and maintain undetectable HBV DNA. For HBeAg‐negative patients, to stop NA treatment is not recommended. In addition to other factors, serum HBsAg titres during treatment have recently been proposed to guide NA‐based therapy duration in selected patients. All patients could be stopped from taking treatment if they achieve HBsAg loss.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24373092</pmid><doi>10.1111/liv.12398</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2014-02, Vol.34 (s1), p.146-153 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1496886134 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adenine - analogs & derivatives Algorithms Antiviral Agents - therapeutic use Biomarkers - blood chronic hepatitis B DNA DNA, Viral - blood Drug Therapy, Combination - methods Drug Therapy, Combination - trends Guanine - analogs & derivatives Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Humans Interferon-alpha - therapeutic use Lamivudine nucleos(t)ide analogues Nucleosides - therapeutic use Organophosphonates Polyethylene Glycols - therapeutic use Recombinant Proteins - therapeutic use Tenofovir Thymidine - analogs & derivatives treatment |
| title | New therapeutic perspectives in HBV: when to stop NAs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A39%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20therapeutic%20perspectives%20in%20HBV:%20when%20to%20stop%20NAs&rft.jtitle=Liver%20international&rft.au=P%C3%A9rez-Cameo,%20Cristina&rft.date=2014-02&rft.volume=34&rft.issue=s1&rft.spage=146&rft.epage=153&rft.pages=146-153&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12398&rft_dat=%3Cproquest_pubme%3E1490753105%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490753105&rft_id=info:pmid/24373092&rfr_iscdi=true |